









Markets
/
Stocks
/
nasdaq-ibio
/

iBio Inc

IBIO

0.859USD

-0.011-1.24%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

16.62MMarket Cap

LossP/E TTM



iBio Inc

0.859

-0.011-1.24%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

205 / 506

Overall Ranking

330 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.200

Target Price

+382.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 400.00K.

Overvalued

The company’s latest PE is -2.73, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.23M shares, decreasing 14.50% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 143.86K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.13.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.25, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 200.00K, representing a year-over-year increase of 14.29%, while its net profit experienced a year-over-year increase of 33.62%.

Score

Industry at a Glance

Previous score

6.25

Change



Financials

7.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.52

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.77, which is 117.24% below the recent high of -6.01 and -876.21% above the recent low of -27.02.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 205/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for iBio Inc is 5.00, with a high of 6.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.200

Target Price

+382.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

iBio Inc

IBIO

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.43, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.98 and the support level at 0.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.43

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.007

Neutral

RSI(14)

54.229

Neutral

STOCH(KDJ)(9,3,3)

31.557

Sell

ATR(14)

0.063

High Vlolatility

CCI(14)

-12.805

Neutral

Williams %R

55.477

Sell

TRIX(12,20)

0.871

Buy

StochRSI(14)

22.342

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

0.866

Sell

MA10

0.880

Sell

MA20

0.849

Buy

MA50

0.759

Buy

MA100

0.800

Buy

MA200

1.984

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 19.57%, representing a quarter-over-quarter decrease of 4.16%. The largest institutional shareholder is The Vanguard, holding a total of 143.86K shares, representing 0.73% of shares outstanding, with 8.44% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

862.28K

Ikarian Capital LLC

599.91K

Crutcher (Patrick J)

696.71K

Opaleye Management Inc.

375.00K

Boothbay Fund Management, LLC

159.45K

The Vanguard Group, Inc.

Star Investors

143.86K

+96.68%

Geode Capital Management, L.L.C.

102.61K

+22.45%

BlackRock Institutional Trust Company, N.A.

42.73K

+666.54%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.96, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.